166 related articles for article (PubMed ID: 32475902)
1. Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naïve Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study.
Okajima F; Sugihara H; Emoto N
J Nippon Med Sch; 2021 Mar; 88(1):71-79. PubMed ID: 32475902
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
3. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
[TBL] [Abstract][Full Text] [Related]
4. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Pratley RE; Fleck P; Wilson C
Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
[TBL] [Abstract][Full Text] [Related]
7. Alogliptin: safety, efficacy, and clinical implications.
Marino AB; Cole SW
J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Wang W; Bu R; Su Q; Liu J; Ning G
Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
[TBL] [Abstract][Full Text] [Related]
10. The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Fujii Y; Abe M; Higuchi T; Mizuno M; Suzuki H; Matsumoto S; Ito M; Maruyama N; Okada K; Soma M
Expert Opin Pharmacother; 2013 Feb; 14(3):259-67. PubMed ID: 23289982
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.
Takebayashi K; Sakurai S; Suzuki T; Hori K; Terasawa T; Naruse R; Hara K; Suetsugu M; Tsuchiya T; Aoki H; Hamasaki T; Shuutou H; Inukai T
Endocr J; 2014; 61(10):1031-9. PubMed ID: 25185672
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
Masuda K; Aoki K; Kamiko K; Takihata M; Ito Y; Nagakura M; Kawasaki S; Akema N; Hasegawa M; Nakajima S; Shinoda K; Toumura S; Tsunoda S; Enomoto H; Shimotomai H; Terauchi Y
Expert Opin Pharmacother; 2013 Jun; 14(9):1111-8. PubMed ID: 23600363
[TBL] [Abstract][Full Text] [Related]
14. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
[TBL] [Abstract][Full Text] [Related]
15. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study.
Tsujino D; Nishimura R; Taki K; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2011 Mar; 13(3):303-8. PubMed ID: 21291335
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
Curr Med Res Opin; 2011 Sep; 27(9):1781-92. PubMed ID: 21806314
[TBL] [Abstract][Full Text] [Related]
17. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.
Kutoh E; Ukai Y
Endocrine; 2012 Jun; 41(3):435-41. PubMed ID: 22249941
[TBL] [Abstract][Full Text] [Related]
18. Alogliptin benzoate for management of type 2 diabetes.
Saisho Y
Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
[TBL] [Abstract][Full Text] [Related]
20. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
Johnston PS; Lebovitz HE; Coniff RF; Simonson DC; Raskin P; Munera CL
J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
